Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. operates as a subsidiary of Skinvisible, Inc. more
Time Frame | QNRX | Sector | S&P500 |
---|---|---|---|
1-Week Return | -4.93% | -1.8% | -0.77% |
1-Month Return | 20.31% | -3.48% | 0.71% |
3-Month Return | 13.67% | -7.2% | 8.81% |
6-Month Return | 4.21% | -1.54% | 12.32% |
1-Year Return | -83.76% | 8.39% | 30.57% |
3-Year Return | -99.84% | 6.07% | 29.21% |
5-Year Return | -99.94% | 44.07% | 91.95% |
10-Year Return | -99.99% | 106.3% | 196.04% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 227.06K | 104.77K | 104.11K | 103.64K | 103.44K | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":46.14,"profit":true},{"date":"2021-12-31","value":45.85,"profit":true},{"date":"2022-12-31","value":45.64,"profit":true},{"date":"2023-12-31","value":45.56,"profit":true}] |
Gross Profit | (227.06K) | (104.77K) | (104.11K) | (103.64K) | (103.44K) | [{"date":"2019-12-31","value":-22705500,"profit":false},{"date":"2020-12-31","value":-10477300,"profit":false},{"date":"2021-12-31","value":-10411500,"profit":false},{"date":"2022-12-31","value":-10363500,"profit":false},{"date":"2023-12-31","value":-10343800,"profit":false}] |
Gross Margin | (Infinity%) | (Infinity%) | (Infinity%) | (Infinity%) | (Infinity%) | [{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false}] |
Operating Expenses | 1.56M | 1.67M | 6.06M | 9.26M | 9.38M | [{"date":"2019-12-31","value":16.64,"profit":true},{"date":"2020-12-31","value":17.81,"profit":true},{"date":"2021-12-31","value":64.65,"profit":true},{"date":"2022-12-31","value":98.71,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (1.56M) | (2.05M) | (20.37M) | (8.85M) | (9.38M) | [{"date":"2019-12-31","value":-156040100,"profit":false},{"date":"2020-12-31","value":-204834300,"profit":false},{"date":"2021-12-31","value":-2037217900,"profit":false},{"date":"2022-12-31","value":-884869500,"profit":false},{"date":"2023-12-31","value":-937850400,"profit":false}] |
Total Non-Operating Income/Expense | 1.55M | (472.38K) | (2.46M) | (742.13K) | 1.33M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-30.47,"profit":false},{"date":"2021-12-31","value":-158.4,"profit":false},{"date":"2022-12-31","value":-47.87,"profit":false},{"date":"2023-12-31","value":85.85,"profit":true}] |
Pre-Tax Income | (1.56M) | (2.10M) | (21.46M) | (9.38M) | (8.66M) | [{"date":"2019-12-31","value":-156040100,"profit":false},{"date":"2020-12-31","value":-209536400,"profit":false},{"date":"2021-12-31","value":-2146258800,"profit":false},{"date":"2022-12-31","value":-938149600,"profit":false},{"date":"2023-12-31","value":-866418900,"profit":false}] |
Income Taxes | 1.55M | (331.31K) | (12.94M) | (104.04K) | 22.38K | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-21.37,"profit":false},{"date":"2021-12-31","value":-834.89,"profit":false},{"date":"2022-12-31","value":-6.71,"profit":false},{"date":"2023-12-31","value":1.44,"profit":true}] |
Income After Taxes | (3.11M) | (1.76M) | (8.52M) | (9.28M) | (8.69M) | [{"date":"2019-12-31","value":-311077600,"profit":false},{"date":"2020-12-31","value":-176405200,"profit":false},{"date":"2021-12-31","value":-851866800,"profit":false},{"date":"2022-12-31","value":-927745300,"profit":false},{"date":"2023-12-31","value":-868657300,"profit":false}] |
Income From Continuous Operations | (1.56M) | (2.10M) | (21.46M) | (9.38M) | (8.64M) | [{"date":"2019-12-31","value":-156040100,"profit":false},{"date":"2020-12-31","value":-209536400,"profit":false},{"date":"2021-12-31","value":-2146258800,"profit":false},{"date":"2022-12-31","value":-938149600,"profit":false},{"date":"2023-12-31","value":-863765500,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (1.56M) | (1.76M) | (8.52M) | (9.28M) | (8.69M) | [{"date":"2019-12-31","value":-156040100,"profit":false},{"date":"2020-12-31","value":-176405200,"profit":false},{"date":"2021-12-31","value":-851866800,"profit":false},{"date":"2022-12-31","value":-927745300,"profit":false},{"date":"2023-12-31","value":-868657300,"profit":false}] |
EPS (Diluted) | (6.91) | (0.10) | (315.89) | (7.09) | (6.50) | [{"date":"2019-12-31","value":-690.69,"profit":false},{"date":"2020-12-31","value":-10,"profit":false},{"date":"2021-12-31","value":-31588.59,"profit":false},{"date":"2022-12-31","value":-709,"profit":false},{"date":"2023-12-31","value":-650,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
QNRX | |
---|---|
Cash Ratio | 2.97 |
Current Ratio | 3.02 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
QNRX | |
---|---|
ROA (LTM) | -36.32% |
ROE (LTM) | -100.03% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
QNRX | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.52 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.48 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
QNRX | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 0.72 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
Quoin Pharmaceuticals Ltd DRC (QNRX) share price today is $0.77
Yes, Indians can buy shares of Quoin Pharmaceuticals Ltd DRC (QNRX) on Vested. To buy Quoin Pharmaceuticals Ltd DRC from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in QNRX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Quoin Pharmaceuticals Ltd DRC (QNRX) via the Vested app. You can start investing in Quoin Pharmaceuticals Ltd DRC (QNRX) with a minimum investment of $1.
You can invest in shares of Quoin Pharmaceuticals Ltd DRC (QNRX) via Vested in three simple steps:
The 52-week high price of Quoin Pharmaceuticals Ltd DRC (QNRX) is $5.33. The 52-week low price of Quoin Pharmaceuticals Ltd DRC (QNRX) is $0.48.
The price-to-earnings (P/E) ratio of Quoin Pharmaceuticals Ltd DRC (QNRX) is
The price-to-book (P/B) ratio of Quoin Pharmaceuticals Ltd DRC (QNRX) is 0.72
The dividend yield of Quoin Pharmaceuticals Ltd DRC (QNRX) is 0.00%
The market capitalization of Quoin Pharmaceuticals Ltd DRC (QNRX) is $3.94M
The stock symbol (or ticker) of Quoin Pharmaceuticals Ltd DRC is QNRX